Gongwin Biopharm Holdings Co. Ltd.
6617.TWO
| Exchange: | TWO |
| Currency | New Taiwan Dollar |
| Fiscal Year End: | December |
| Sector: | Healthcare |
| Industry: | Biotechnology |
| Description: | Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of liver cancer; PTS-02 for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company was founded in 2014 and is based in Taipei, Taiwan. |
| Address: | No. 80, Jianguo North Road, Taipei, Taiwan, 104 |
| Website: | https://www.gongwinbiopharm.com |
| Updated On: | 2024-11-09 |
Highlights
| Market Capitalization: | 14559229952 |
| Market Capitalization Mln: | 14559.23 |
| EBITDA: | -130031000 |
| Book Value: | 25.99 |
| Earnings Share: | -0.89 |
| Most Recent Quarter: | 2024-06-30 |
| Operating Margin TTM: | -3.76 |
| Return On Assets TTM: | -0.03 |
| Return On Equity TTM: | -0.04 |
| Revenue TTM: | 31708000 |
| Revenue Per Share TTM: | 0.27 |
| Quarterly Revenue Growth YOY: | 6.39 |
| Diluted Eps TTM: | -0.89 |
Valuation
| Price Sales TTM: | 459.16 |
| Price Book MRQ: | 4.39 |
| Enterprise Value: | 11775773000 |
| Enterprise Value Revenue: | 371.38 |
| Enterprise Value Ebitda: | -167.23 |
Shares
| Shares Outstanding: | 126602000 |
| Shares Float: | 59102856 |
| Percent Insiders: | 52.79 |
| Percent Institutions: | 0.05 |
Technicals
| Beta: | 0.77 |
| 52 Week High: | 223.5 |
| 52 Week Low: | 96 |
| 50 Day MA: | 116.3 |
| 200 Day MA: | 154.22 |